Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | HBB | P68871 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20866 | 0.79 | ATAD2 (0.41) | ALDH1A1HPGDKDM4EADORA3ATAD2 | |
| SCHEMBL2118527 | 0.72 | PDPK1 (0.44) | ALDH1A1TP53HPGDPTGS1HBB | |
| SCHEMBL26948743 | 0.72 | ADORA2B (0.42) | ALDH1A1TP53HPGDPTGS1HBB | |
| Trifluoroacetic Acid SCHEMBL2300169 | 0.69 | KDM4E (0.35) | ALDH1A1HPGDKDM4EADORA3ATAD2 | |
| SCHEMBL2117280 | 0.69 | ALDH1A1 (0.39) | ALDH1A1TP53HPGDPTGS1HBB | |
| SCHEMBL15347874 | 0.69 | CHRNB2 (0.39) | ALDH1A1ADORA3BTKATAD2LMNA | |
| SCHEMBL667794 | 0.67 | PDE4A (0.49) | HPGDADORA3ADORA2AADORA2BPDE4A | |
| SCHEMBL10597939 | 0.67 | PNP (0.33) | ADORA3ATAD2LMNACYP1A2MAPT | |
| SCHEMBL8886026 | 0.67 | PNP (0.35) | ADORA3ATAD2LMNACYP1A2MAPT | |
| SCHEMBL3259641 | 0.67 | PNP (0.35) | ALDH1A1ADORA3ATAD2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103877-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720094-A1 | MUTATED FRAGMENT OF VZV GLYCOPROTEIN E | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260061042-A1 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250387764-A1 | COAXIAL FLOW DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH DEVICE | PFIZER INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382323-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR DETECTING NUCLEOTIDES | AXBIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | ALDH1A1 4457/4885TP53 2406/4885HPGD 4612/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | ALDH1A1 4675/4885TP53 1086/4885HPGD 1971/4885 |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | NPC1, NPC1L1, PLIN3 | ALDH1A1 4206/4885TP53 2179/4885HPGD 4111/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | ALDH1A1 4429/4885TP53 771/4885HPGD 4496/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | ALDH1A1 4755/4885TP53 1151/4885HPGD 4041/4885 |
| US-20250387764-A1 | COAXIAL FLOW DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH DEVICE | POLRMT, MTREX, PHAX | ALDH1A1 3073/4885TP53 190/4885HPGD 1064/4885 |
| US-20260061042-A1 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | SELP, LNPEP, NOP2 | ALDH1A1 4401/4885TP53 321/4885HPGD 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.